Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.
AbbVie contractor 340B ESP posted a policy update from AbbVie on its website on March 1. The six-page document appears to be nearly identical to AbbVie’s original late December 2021 notice to covered entities except for two small changes on the last page—Imbruvica’s inclusion on the list of covered products, and a short note below the list stating, “340B Integrity Initiative will become effective for Imbruvica on April 1, 2022.”
Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
